Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML These findings underscore the need to screen for and address mental health concerns among AYA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback